Market Overview - A-shares showed mixed performance on July 7, with the Shanghai Composite Index closing at 3473.13 points, up 0.02%, while the Shenzhen Component and ChiNext Index fell by 0.70% and 1.21% respectively [1] - The total market turnover was 12.27 billion yuan, a decrease of 2.27 billion yuan from the previous trading day [1] Real Estate Sector - The real estate sector experienced a rebound, with stocks like Yuhua Development and Shahe Shares hitting the daily limit [2] - The Ministry of Housing and Urban-Rural Development emphasized the need for safe, comfortable, green, and smart housing, aiming to stabilize expectations and activate demand [2] - Guojin Securities noted that the third quarter is crucial for real estate policy implementation, which could significantly impact the market in the latter half of the year [2] Power Sector - Power stocks surged due to the summer electricity peak, with companies like Shaoneng Shares and Huayin Power hitting the daily limit [3] - Huayin Power projected a net profit of 180 million to 220 million yuan for the first half of 2025, an increase of 175 million to 215 million yuan year-on-year [3] - National electricity load reached a record high of 1.465 billion kilowatts, with significant increases in several provinces [3] Electricity Market Outlook - Xiangcai Securities expects high electricity demand to continue, improving the power supply-demand balance [4] - The firm recommends focusing on three main areas: hydropower assets benefiting from market reforms, thermal power stocks with improving performance, and leading companies in renewable energy [4] Market Sentiment - China Galaxy Securities indicated that the market is in a rapid rotation phase, with increased volatility expected due to upcoming earnings reports and external uncertainties [5] - The firm suggests focusing on sectors with relatively high earnings certainty in the short term, while maintaining a positive long-term outlook for A-shares [5] Investment Strategy - Recommendations include focusing on assets with high safety margins, technology as a long-term investment theme, consumer sectors boosted by policy support, and mergers and acquisitions [6]

当前中国创新药行业的估值水平如何？未来可能有多大空间？ 从年初至今，港股创新药指数上涨了 69%。本轮收益的主要驱动因素是中国创 新药全球竞争力的突破、对外授权的爆发以及多个重磅产品即将在美国上市销 售。国内政策环境也较为支持，百济神州、信达生物等头部公司将走向盈利。 目前港股创新药指数的 PS 和 PB 均回到了历史中位数水平左右，而恒生医疗保 健指数虽然 PS 有所回升，但仍处于历史底部区间。 对比海外情况，礼来公司 的 PS 从 2021 年的 5 倍提升到现在的 15 倍，日本中外制药从 2013 年的 4 倍 提升到现在的 11 倍。因此，我们认为中国创新药目前处于全球竞争力突破时 点，PS 显著提升是必然趋势。目前 ARJEX 市值约为 330 亿美元，而百济神州 市值约为 290 亿美元，相对较低。其他如信达、康方、科伦博泰、百利天恒、 新诺威等公司，其产品具有百亿美金销售潜力，但当前市值仍显著低于 ARJEX。 考虑到中国创新药企收入快速增长及海外市场拓展空间，未来 5-10 全球 ADC 市场快速增长，国内 ADC 资产展现出出色潜力，多家公司针 对不同靶点推出新药并陆续出海，如科伦博泰的 ...

Report Industry Investment Rating No relevant content provided. Core View of the Report - Appropriate realization and waiting for layout opportunities. Currently, the convertible bond market is facing supply - demand contradictions and high valuations. In the context of potential increased volatility in the equity market, convertible bonds may face valuation adjustment pressure. Short - term investment should focus on large - cap debt - biased varieties, avoid bonds with overly high downward - revision expectations, realize profits appropriately, maintain a flexible position, and wait for the next layout opportunity [2][45]. Summary According to the Directory 1. Appropriate Realization, Waiting for Layout Opportunities - **Market Performance in Q2**: The equity market showed a deep "V" trend in Q2. The convertible bond index rose 3.4%, outperforming the Shanghai Composite Index. The low - price index rose 2.7%, and the equal - weighted index rose over 4% [12]. - **Supply - demand Analysis**: In Q2, convertible bond supply accelerated, with 11 new issues and a scale of 8 billion yuan. However, due to maturities and forced redemptions, the total scale decreased by over 55 billion yuan compared to Q1. The short - term supply supplement is limited. On the demand side, it first decreased and then increased. In June, there was a large - scale capital inflow [13][21]. - **Valuation Analysis**: The valuation of balanced convertible bonds rose significantly at the end of June, breaking through the annual high. The valuation of debt - biased convertible bonds reached a historical high, while the valuation of equity - biased convertible bonds remained at a low level [39][40]. 2. Market Review 2.1 Equity Market: Index Continued to Rise Strongly - **Index Performance**: Last week, the Shanghai Composite Index and the ChiNext Index rose 1.4% and 1.5% respectively. The market trading volume rebounded, and the theme hotspots rotated actively [47]. - **Style and Sector Performance**: Industries such as steel and building materials led the rise, while the banking sector reached a new high for the year. Some sectors such as computer and non - bank finance declined [47]. - **Valuation**: The PE (TTM) of all A - shares was 15.76X, and the PE (TTM) of the ChiNext was 36.38X, both showing an upward trend [48]. 2.2 Convertible Bond Market: Valuation Continued to Rise - **Index and Trading Volume**: The CSI Convertible Bond Index closed at 447.46, rising 1.21%. The average daily trading volume was 64.766 billion yuan, a 11.85% increase from the previous period [54]. - **Individual Bond Performance**: Dianhua, Saili, and Anke led the gains, while Jinji, Sanyang, and Jingduan led the losses [54]. - **Valuation**: The conversion premium rate of convertible bonds with a parity of 90 - 110 was 26.42%, and the average YTM of convertible bonds with a parity below 80 was - 0.27%, indicating a significant increase in valuation [56]. 3. Convertible Bond Investment Strategy 3.1 Stock Market - In the short term, the external uncertainty has increased significantly, and the index volatility may intensify. The broad - based index will be in a volatile state, and investors can focus on sectors such as innovative drugs, self - controllability, AI +, and solid - state batteries, as well as industries with improved prosperity [3]. 3.2 Convertible Bonds - The overall view is neutral and cautious, preferring structural individual bond opportunities. Specific areas to focus on include TMT, robotics, low - altitude areas, innovative drugs, debt - resolution directions, price - rising cyclical sectors, bottom - position bonds, and newly - listed bonds [4]. 3.3 Primary Market Tracking - Last week, 2 new convertible bonds were issued, 1 convertible bond was approved by the shareholders' meeting, and 1 convertible bond issuance was accepted by the exchange [5][68].

以下文章来源于创业板观察 ，作者闫军 创业板观察 . 债券基金新发上，10只科创债ETF的发行备受关注，其中7只仅售一天。此外，华夏、创金合信各有一只REIT今日发行。 创业板观察致力于发布深交所创业板的市场发展、政策变化、监管导向、上市企业动态等的及时信息，提供有价值的市场资讯。 随着市场行情升温，基金公司也积极备战下半年发行市场"开门红"。 7月7日至11日当周，全市场再迎来39只基金面市， 仅7月7日（本周一）就有31只基金迎来发行。 新发基金类型众多，涵盖主动权益、ETF 以及联接基金、量化基金、债券ETF、纯债基金以及REITs等。其中权益基金依然是主角，仅7月7日来看，权益基金新发数量最多，为17 只，ETF及联接基金为11只，主动权益发行回暖，大成、鹏扬、摩根资管等6家公司新发产品。 今年以来，在AI、半导体、创新药等科技板块轮动走强的背景下，成长风格产品发行也愈发积极，从布局风格来看，红利主题基金、机器 人、航天航空、科创芯片均获有产品新发。 权益基金依然是发行的主角，成长风格占优 发行市场上，权益依然是最大的战场，7月7日新发基金来看，17只权益基金，其中6只为主动权益，11只为ETF及相关 ...

Core Viewpoint - Ganli Pharmaceutical showcased its self-developed GLP-1 receptor agonist, Bofanglureptide (GZR18), and insulin formulation GZR4 at the 85th American Diabetes Association (ADA) conference, attracting significant attention in the global metabolic disease community [1] Group 1: Company Performance and Market Position - Ganli Pharmaceutical's performance has significantly reshaped investor expectations, with multiple institutions recognizing it as a leading domestic insulin provider, entering a performance release phase due to price and volume increases from procurement renewals and breakthroughs in innovative pipelines [2][3] - The company achieved a 32.6% overall increase in procurement volume, with its three generations of insulin accounting for 30% of the market, leading to substantial sales growth [4] - The international revenue reached 528 million yuan, a year-on-year increase of 23.89%, demonstrating Ganli's capability in global supply chain and cost efficiency management [5] Group 2: Research and Development - Ganli Pharmaceutical invested 646 million yuan in R&D in 2024, representing 21.2% of its revenue, focusing on metabolic diseases [4] - The II phase clinical results for GZR4 and Bofanglureptide showed significant potential in improving HbA1c levels and weight loss compared to existing treatments, indicating a strong clinical advantage [4][7] Group 3: Competitive Landscape and Market Strategy - The implementation of centralized procurement policies has led to a structural shift in the Chinese insulin market, with Ganli's market share increasing from 19% to 37% [6] - Ganli's pricing strategy positions its insulin products at 70%-80% of the prices of competitors like Novo Nordisk, while demonstrating equivalent efficacy through equivalence studies [6][7] Group 4: Future Outlook and Globalization - If Bofanglureptide successfully enters the market, it could tap into a global obesity treatment market worth $20 billion, highlighting the long-term growth potential for Ganli [2] - Ganli is positioned as a benchmark for Chinese innovative drugs on a global scale, with the potential to capture significant market share in the evolving diabetes treatment landscape [8]

策略定期研究 2025 年 7 月 7 日 国内宏观和产业政策周观察（0630-0706） 支持创新药高质量发展 投资要点： 本周政策聚焦产业数字化升级与金融制度创新，监管层启动工业产品生 产许可体系改革，强化标准化与智能化管理。资本市场方面，深交所出台 "轻资产、高研发投入"认定标准，提升创业板对科技企业的包容性。医疗 领域推动医保数据向创新药研发开放，促进"医、药、保"协同发展。交通 运输方面，"空铁联运"三年任务清单发布，推进多式协同与信息共享机制 建设。整体来看，政策持续围绕科技赋能、高质量发展和制度优化发力，助 推传统行业转型升级与新兴动能培育。 本周A股各大板块涨跌不一。其中，涨幅排名前五的是钢铁Ⅱ (+5.98%)、 建材Ⅱ (+4.33%)、医药生物 (+4.33%)、银行 (+3.78%)、电气设备 (+2.44%)。 跌幅前五的是软件服务 (-1.05%)、半导体 (-0.89%)、家庭用品 (-0.74%)、企 业服务 (-0.71%)、交通运输 (-0.43%)。 本周热门概念中，涨幅排名前十的为CRO (+7.08%)、创新药 (+6.99%)、 水产 (+6.42%)、光伏屋顶 ( ...

证券研究报告：医药生物|行业周报 发布时间：2025-07-07 行业投资评级 强于大市 |维持 | 行业基本情况 | | | --- | --- | | 收盘点位 | 7952.02 | | 52 周最高 | 8490.25 | | 52 周最低 | 6070.89 | 行业相对指数表现 2024-07 2024-09 2024-11 2025-02 2025-04 2025-07 -7% -3% 1% 5% 9% 13% 17% 21% 25% 29% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:陈成 SAC 登记编号:S1340524020001 Email:chencheng@cnpsec.com 近期研究报告 《RDC 引领核药行业快速崛起，开启诊 疗一体化时代》 - 2025.07.04 医药生物行业报告 （2025.06.30-2025.07.04） PD-(L)1/VEGF双抗BD预期引发创新药行情持续 热潮 l 一周观点：PD-(L)1/VEGF ...

2025年上半年，创新药板块的崛起成为投资市场的一大亮点。在政策支持、技术突破以及市场需求的多重驱动下，创 新药相关基金业绩表现突出，成为基金收益的关键驱动力，也成为主动权益为自己"正名"的关键一战。 创新药终于迎来了春天 主动权益正在回归 上半年收官，2025年上半场的激烈角逐尘埃落定。A股市场延续了震荡分化的特征，成长、消费、周期板块轮动加速。 一个显著的特点是，主动权益基金重新跑赢宽基指数。根据Wind的数据统计，今年上半年偏股基指数上涨7.86%，偏 股混基金收益率中位数为4.81%，75%的偏股混合型基金实现了正收益。从目前的表现看，今年大概率会成为主动权益 基金跑赢宽基指数的一年。 就着半年度的节点，我们也拉了一份上半年业绩TOP10的基金成绩单： 自今年4月9日触底反弹以来，A股、港股的创新药板块持续走强。截至6月30日，万得创新药概念指数涨超21%，恒生 创新药指数更是涨超66%。其中，张韡管理的汇添富香港优势精选A（470888）以86.48%的净值增长荣登2025年上半 年业绩榜首。 Wind数据显示，截至6月30日，汇添富香港优势精选A、中信建投北交所精选两年定开A、长城医药产业精选A跻 ...

行业周报 行业评级： | 报告期：2025.6.23-2025.7.6 | | | --- | --- | | 投资评级 | 看好 | | 评级变动 | 维持评级 | 本报告期医药生物行业指数涨幅为 5.30%，在申万 31 个一级行业中 位居第 14，跑赢沪深 300 指数（3.52%）。从子行业来看，其他生物 制品、医疗研发外包涨幅居前，涨幅分别为 11.20%、9.37%；医疗设 备、血液制品涨幅居后，涨幅均为 0.98%。 行业走势： 估值方面，截至 2025 年 7 月 4 日，医药生物行业 PE（TTM 整体法， 剔除负值）为 28.52x（上期末为 27.28x），估值上行，低于均值。医 药生物申万三级行业 PE（TTM 整体法，剔除负值）前三的行业分别 为疫苗（54.13x）、医院（36.88x）、其他生物制品（34.72x），中 位数为 29.22x，医药流通（15.20x）估值最低。 XXXX@gwgsc.com 本报告期，两市医药生物行业共有 34 家上市公司的股东净减持 4.92 亿元。其中，7 家增持 5.09 亿元，27 家减持 10.01 亿元。 2025 年 7 月 7 日 证 ...

Overall Market Performance - The Shanghai Composite Index experienced a narrow fluctuation throughout the day, closing up by 0.02% at 3473.13, while the Shenzhen Component Index fell by 0.70% to 10435.51, and the ChiNext Index dropped by 1.21% to 2130.19 [1][2] Sector Performance - The cross-border payment and stablecoin concepts were notably active, with stocks such as Zhongyi Technology, Jingbeifang, and Xinyada hitting the daily limit up [1] - Real estate stocks saw a midday surge, with companies like Yudai Development, Shahe Shares, and Nanshan Holdings also reaching the daily limit up [1] - Conversely, the innovative drug sector experienced a pullback, with Kexing Pharmaceutical declining over 14% [1] Popular Concepts - Power stocks surged against the trend, with nearly ten stocks including Shaoneng Shares, Huayin Electric, and Shimao Energy hitting the daily limit up [1]